Table 6 Studies on BRAF mutation status in colorectal cancer patients
From: The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients
Reference (year) | Country | BRAF mutation % (n) | BRAF mutation type (%) | Methods | Prognostic value | Comments |
|---|---|---|---|---|---|---|
Pai et al. (2012) [36] | USA | 11.0 (20) | V600E (100) | real-time PCR | Significant | Stage I-IV proficient DNA mismatch repair |
Kadowaki et al. (2015) [37] | Japan | 4.9 (40) | V600E (80) | PCR combined with restriction enzyme digestion | Significant | Stage I-III independent of MSI status |
Chen et al. (2014) [38] | China | 4.2 (9) | V600E (88.9) | direct sequencing | Significant | Stage I-IV |
Siraj et al. (2014) [39] | Saudi Arabia | 2.5 (19) | V600E (89.5) | direct sequencing | No prognostic significance | Stage I-IV |
Ahn et al. (2014) [40] | Korea | 15.9 (26) | V600E (100) | PNA clamp real-time PCR | Significant | Stage I-IV |
Kim et al. (2014) [41] | Korea | 9.6 (13) | N/A | direct sequencing | Significant | Stage III-IV |
Yaeger et al. (2014) [42] | USA | 5 (92) | V600E (96.7) | mass spectrometry-based assay | Significant | Metastatic colorectal cancers |
Eklof et al. (2013) [43] | Sweden | 17.9 (35) 13.2 (54) | V600E (100) | allelic discrimination assay | Significant No prognostic significance | Stage I-IV two different cohorts |
Renaud et al. (2015) [44] | France | 10.6 (19) | V600E (100) | direct sequencing | Significant | Metachronous lung metastasis |
de Cuba et al. (2015) [45] | Netherlands | 51.0 (73) | V600E (100) | high resolution melting and sequencing | Significant | Stage II and III microsatellite instable colon cancers |
Foltran et al. (2015) [46] | Italy | 5.2 (10) | V600E (100) | pyrosequencing | Significant | Metastatic colorectal cancers |
Tsai et al. (2015) [47] | Taiwan | 18.6 (11) | V600E (100) | direct sequencing | Significant | Stage I-IV early-onset colorectal cancers |
Saridaki et al. (2013) [48] | Greece | 8.2 (41) | V600E (100) | real-time PCR | Significant | Metastatic colorectal cancers |
Kalady et al. (2012) [49] | USA | 11.7 (56) | V600E (98.2) | direct sequencing | Significant | Stage I-IV |
Farina-Sarasqueta et al. (2010) [50] | Netherlands | 19.9 (59) | V600E (100) | real-time PCR | Significant | Stage II and III independently of disease stage and therapy. |
Present case | Korea | 4.0 (44) | V600E (97.7) | direct sequencing | Significant | Stage I-IV Significant prognostic implications through all stages |